Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Periarticular Penetration of Cefazolin and Clindamycin in Hip Revision
NCT05421312Phase 4Unknown
- Sponsor
- Radboud University Medical Center
- Start
- Sep 2022
- Primary completion
- Sep 2023
- Modality
- Reversible Covalent Inhibitors
01
Overview
Phase 4, open-label, single-arm trial of cefazolin and clindamycin in periprosthetic joint infection (PJI), sponsored by Radboud University Medical Center. Primary endpoints: Penetration of cefazolin into synovial fluid, Penetration of cefazolin into bone tissue and 1 more. Status: unknown.
02
Drugs
cefazolinclindamycin
03
Conditions
periprosthetic joint infection (PJI)
Beyond the preview
Go deeper on NCT05421312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05421312.